, Thomas S. Griffith 4 and Salih Sanlioglu 1,2, * Despite the fact that insulin injection can protect diabetic patients from developing diabetes-related complications, recent meta-analyses indicate that rapid and long-acting insulin analogues only provide a limited benefit compared with conventional insulin regarding glycemic control. As insulin deficiency is the main sequel of type-1 diabetes (T1D), transfer of the insulin gene-by-gene therapy is becoming an attractive treatment modality even though T1D is not caused by a single genetic defect. In contrast to human insulin and insulin analogues, insulin gene therapy targets to supplement patients not only with insulin but also with C-peptide. So far, insulin gene therapy has had limited success because of delayed and/or transient gene expression. Sustained insulin gene expression is now feasible using current gene-therapy vectors providing patients with basal insulin coverage, but management of postprandial hyperglycaemia is still difficult to accomplish because of the inability to properly control insulin secretion. Enteroendocrine cells of the gastrointestinal track (K cells and L cells) may be ideal targets for insulin gene therapy, but cell-targeting difficulties have limited practical implementation of insulin gene therapy for diabetes treatment. Therefore, recent gene transfer technologies developed to generate authentic beta cells through transdifferentiation are also highlighted in this review. ) and the presence of a regulated secretory pathway, but these cells lack glucose responsiveness because they do not express glucokinase (GK) and glucose transporter-2 (GLUT2). The fact that these cells secrete adrenocorticotropic hormone involved in glucocorticoid synthesis, which inhibits insulin action, eliminates their future utility as a treatment modality for diabetes. Consequently, recombinant insulin production in nonbeta cells in vivo has become a major research interest alternative to insulin injection and/or pancreatic islet cell transplantation. The objective of insulin gene therapy is to genetically manipulate nonbeta cells to synthesise, store and secrete insulin-like pancreatic beta cells. One advantage of using nonbeta cells instead of beta cells is that they are resistant to the beta cellspecific autoimmune response present in T1D patients (Ref. 3) . Moreover, an insulin gene transfer system should possess a number of key features to increase the chance for successful therapy. First, the system should provide an effective gene delivery method to the target organ. Second, the target organ should have glucose-sensing machinery, especially GLUT2 and GK, and the necessary biochemical processing components to convert proinsulin to mature insulin. Third, the target cells should have storage capacity and a regulated secretory pathway inducible by glucose. Finally, transcription of the insulin transgene should be induced during hyperglycemia and inhibited during hypoglycemia. 25) . In another approach, a hepatocyte cell line (H4-II-E) was infected with replicationdefective adenovirus carrying the human proinsulin cDNA with the dibasic PC recognition sequence mutated to a tetra-basic furin cleavage site to test the extent to which hepatocytes could constitutively synthesise proinsulin and secrete mature insulin (Ref. 26) . Injection of this viral construct into mice resulted in insulin gene expression mainly in the liver, and transiently reversed diabetes. Similarly, livers of STZ-induced diabetic nude rats were infected with an adenovirus engineered to express rat preproinsulin under the control of the human elongation factor 1-alpha (EF1-alpha) promoter to assess the benefit of sustained hepatic insulin production on glycemic control (Ref. 27) . In this setting, sustained basal expression of plasma insulin significantly reduced both plasma glucagon and glucose levels in diabetic animals. Liver pathology (glycogen breakdown and lipid deposition) associated with T1D was also reduced through constitutive hepatic insulin gene expression at low levels. However, all treated animals developed severe hypoglycemia upon fasting because of the constitutive insulin gene expression.
In contrast to hepatocytes that lack the convertases necessary for processing prohormones into their fully active forms, lung tissue has an abundant supply of neuroendocrine secretory cells that naturally express the PCs. Liposome-mediated transfer of a plasmid containing the rat insulin gene driven by a Cytomegalovirus (CMV) promoter was tested in the lung (Ref. 28) . Multiple transfers yielded a significant increase in insulin gene expression in lung alveolar epithelial cells, as well as the processing and secretion of insulin protein, which lowered hyperglycemia and ketoacidosis in STZinduced diabetic mice without any adverse effect. Nonviral vectors (such as plasmids) are nonimmunogenic and have fewer side effects than viral vectors, but repeated administration is required to sustain a therapeutic effect.
rAAV vectors provide much longer transgene expression compared with first-and secondgeneration adenoviral vectors. Recently, the efficacy of long-term rAAV-mediated insulin gene therapy was demonstrated using rAAV encoding a furin-modified human insulin under the control of CMV promoter (Ref. 29) . Although transient normoglycemia was observed in animals treated with a recombinant adenovirus encoding furin-modified human insulin, rAAV delivery into the portal vein resulted in normoglycemia over 90 days posttreatment in STZ-induced diabetic rats. In addition, sustained insulin production reduced HbA1c levels and improved glucose tolerance without any adverse events. Similarly, Elsner et al. recently tested the therapeutic efficacy of a lentiviral vector encoding furin-cleavable human insulin in autoimmune-diabetic rats and STZdiabetic rats (Ref. 30 ). Blood glucose concentrations were normalised in the treated animals throughout the observation period (about a year), suggesting diabetes could be reversed by a somatic gene therapy approach involving insulin release from nonendocrine cells.
The limited capacity of nonbeta cell to process proinsulin to insulin can be overcome using furin recognition sequence-modified human insulin cDNA; however, coupling insulin expression to metabolic demand, which varies throughout the day, is another major obstacle to overcome.
Insulin gene therapy for enabling physiologic control of insulin gene expression
Glucose regulates many genes in pancreatic beta cells and hepatocytes, making it a potent regulator of insulin production. Beta cells and hepatocytes possess GLUT2 and GK activities for responding to alterations in blood glucose. Glucagon and cyclic AMP (cAMP) induce Phosphoenolpyruvate carboxykinase (PEPCK) promoter activity in hepatocytes, whereas PEPCK promoter activity is downregulated by insulin. Thus, proinsulin DNA engineered to include a furin recognition site driven by the PEPCK promoter creates a regulatable system for targeting hepatocytes as insulin-producing surrogate cells (Ref. 31) . Introduction of such a construct into primary cultured rat hepatocytes using a recombinant adenovirus resulted in mature human insulin production. The use of basal glucose responsive promoters, such as the promoters for rat S-14 or L-PK, in place of PEPCK is less optimal because of their weak promoter activity in liver (Ref. 31 ).
Since constructs with natural glucose regulated promoter-driven insulin expression yield weak transcriptional activities causing failure to suppress nonfasting hyperglycemia, livertargeted insulin gene therapy can occur using synthetic promoters generated from the combination of HNF-1, C/EBP binding elements and GlRE in conjunction with an L-PK promoter (Ref. 32) . Intravenous administration of a recombinant adenovirus expressing furincleavable insulin under the control of a synthetic promoter corrected hyperglycemia and improved glucose tolerance in STZ-induced diabetic nonobese diabetic-severe combined immunodeficiency (NOD-SCID) mice. These results suggest that artificial promoters can be used to regulate glucose-responsive insulin production for liver-directed insulin gene therapy. Constitutive insulin expression via CMV promoter eventually causes death because of hypoglycemia, but constructs containing a glucose responsive enhancer/liver-specific promoter activity result in mild hypoglycemia. In addition, there is still a delay in restoring normoglycemia, as demonstrated by glucose tolerance tests suggesting the necessity of further improvement in the vector design to achieve a negative regulatory response.
As an alternative to using PEPCK and L-PK promoters and the negative response by insulin, a liver-specific albumin promoter with glucose The conversion of glucose-6-phosphate to glucose is catalysed by glucose-6-phosphatase (G6Pase), an enzyme mainly responsible for controlling glucose output from liver. As diabetic patients display increased glucose output from the liver causing fasting hyperglycemia, the G6Pase promoter (Ref. 37) has been used to regulate insulin gene expression in rat hepatoma cell lines. The G6Pase promoter is well suited for this function because it is highly active under diabetic conditions and negatively regulated by insulin (Ref. 38). Glucose-stimulated (but selflimiting) insulin production can be achieved using an adenoviral vector encoding genetically engineered human insulin gene under control of the G6Pase promoter, but transgene expression was low in liver because of the negative feedback by insulin. Thus, incorporation of glucose responsive enhancers to generate stronger promoters is advised as a new approach to produce adequate insulin expression for lowering blood glucose under diabetic setting. For this purpose, a hybrid G6Pase promoter linked to intronic enhancers of the aldolase B gene was used to achieve auto-regulated insulin gene expression in liver (Ref. 39) . Adenoviral delivery of this modified insulin gene to the liver significantly reduced nonfasting hyperglycemia without causing fasting hypoglycemia in STZinduced diabetic nude rats.
Several 43) . Although RIP-directed insulin gene expression in liver resulted in glucose-regulated insulin gene expression, the level of the expression was not sufficient to correct fasting hyperglycemia in diabetic mice.
The rAAV-mediated liver transduction is generally low, therefore, a number of different methods to enhance rAAV-mediated insulin gene delivery to liver have been tested. For example, the effect of calcium phosphate (CaPi) on rAAV-mediated insulin therapy in diabetic animals was investigated using human insulin gene under the control of the PEPCK promoter (Ref. 44) . Although rAAV administration by itself significantly decreased blood glucose levels of diabetic animals, mixing of rAAV with calcium phosphate augmented the hypoglycemic effect of rAAV-mediated insulin gene transfer as well. A rAAV vector harbouring a furin-mutated insulin gene under the control of 410-bp rat insulin 1 promoter was complexed with polyethylenimine (PEI) to investigate the feasibility of glucose-modulated insulin gene therapy for diabetes (Refs 45, 46) . rAAVtransduction of Huh7 cells, a human hepatoma cell line with several endocrine pancreatic celllike features, resulted in the secretion of insulin in response to high glucose levels. Furthermore, use of insulin secreting agents [dibutyryl cAMP, theophylline and forskolin] enhanced glucoseregulated rAAV-mediated transgene expression demonstrating that metabolic regulation can be coupled to hormonal regulation for a better induction of insulin biosynthesis. In addition, glucose challenge stimulated secretion of human insulin and significantly lowered hyperglycemia in the STZ-induced diabetic mice. However, a lag time of 30 min was needed to induce insulin secretion demonstrating slow kinetics of transcriptional regulation. Nevertheless, none of the animals treated with rAAV-PEI complex manifested hypoglycemia. Although PEI treatment enhanced rAAV-mediated transduction in liver, it can cause membrane damage inducing apoptosis.
Furthermore, rAAV encoded transgene products can be immunogenic based on the route of delivery (Ref. 47 ). Thus, immunosuppression of individuals might be necessary to prevent immunity against AAV vectors, which would otherwise limit the efficacy of the treatment (Refs 48, 49).
Insulin gene therapy with pharmacological control of insulin gene expression
The liver is the preferred organ for producing insulin (via gene therapy) once the pancreas can no longer produce insulin, even though physiologic glucose-mediated control of insulin expression is not fully restored in the liver.
Owing to the kinetics of regulation, glucose responsive promoters achieved limited success in regulating blood glucose levels in diabetic animals. For example, insulin gene transcription and translation require several hours to be effective, long after the onset of hyperglycemia. Transcription repression required for shutting down insulin gene expression after achieving normoglycemia also takes time. Consequently, patients may experience prolonged hyperglycemia or hypoglycemia. As constitutive insulin secretion from liver is associated with hypoglycemia, pharmacological stimulation of insulin transcription is tested as a novel approach to gain control of insulin secretion. In this scenario, a pharmacological agent controls a recombinant transcription factor that induces insulin gene expression (Fig. 2) . For example, rapamycin facilitates heterodimer formation between the immunophilin FK506 Binding Protein (FKBP) and the lipid kinase homologue FKBP rapamycin-associated protein (FRAP). FKBP DNA binding is mediated by the ZFHD1 domain, and the rapamycin interacting domain of FRAP is joined to the transcription activation domain of the p65 subunit of necrosis factor-κB. Such a rapamycin-based regulatory system was tested to manage adenovirus-mediated transcription of the furin-cleavable proinsulin gene in diabetic nude mice (Ref. 21) . Adenoviral vectors encoding either wild-type proinsulin (hIns-wt) or a modified proinsulin cleavable by the ubiquitously expressed protease furin (hIns-M3) in association with each of the two beta cellspecific proinsulin convertases, PC2 and PC3, were used to test the therapeutic efficacy and consequence of mature insulin production in liver. Intravenous administration of the adenovirus vector expressing furin-cleavable proinsulin generated higher levels of mature insulin in liver compared with concurrent administration of adenovirus encoding wild-type proinsulin and proinsulin convertases. These data suggest that high-level expression of the mature form of insulin can occur by infecting the liver with an adenovirus encoding a furin cleavable form of proinsulin. Although endogenous PC2 or PC3 expression is not detected in the liver, high levels of furin expression is present. To test the efficacy of the rapamycin inducible system, adenoviral vectors encoding the rapamycin-regulated transcription factor (Ad-CMV-TF1) and an hIns-M3 transgene located downstream of the 12 binding sites for the regulated transcription factor (Ad-Z12-hInsM3) were co-administered into diabetic mice. Insulin secretion from mouse liver was induced only in the presence of rapamycin resulting in the lowering of blood glucose and halting of insulin gene expression upon drug withdrawal.
These results suggest pharmacological regulation of insulin gene transcription in the liver to be a promising alternative for controlling glucose homoeostasis in diabetic animals (Fig. 2) . Although transcriptional control of insulin expression using rapamycin allows dose-dependent induction of circulating levels of insulin alleviating hyperglycemia in diabetic animals, optimum levels of insulin expression required 12 h to generate. Although the approach may not be useful to mimic postprandial acute rise of insulin, it may be helpful to obtain therapeutic baseline levels of insulin expression, an effect similar to that of long-acting insulin.
Current obstacles and future prospects in insulin gene therapy
Hepatocytes constitutively secrete proteins, making it difficult to achieve an instant release expert reviews http://www.expertreviews.org/ in molecular medicine of sufficient amounts of insulin to deal with the postprandial glucose excursions. Recombinant insulin designed to modulate postprandial glucose levels must be produced quickly in bursts following signal recognition. As insulin is stored in secretory granules in beta cells until their release, regulation of insulin secretion is necessary to achieve physiologically controlled insulin production by gene delivery. Thus, direct control of secretion provides faster regulation of blood glucose than transcriptional control. Regulation of insulin secretion through controlled aggregation in the endoplasmic reticulum (ER) is suggested as a novel complementary method to achieve controlled insulin release (Ref. 50 ). In this model, engineered proinsulin is retained in the ER of constitutive secretory cells (Fig. 3) . After induction by an orally administered small molecule, insulin is processed and subsequently released quickly in relatively large amounts since proinsulin is engineered to carry a signal sequence attached to conditional aggregation domains (CAD) -regions necessary to retain target molecules in the ER. In addition, furin cleavage sites are included within the proinsulin encoding sequence to allow post-translational modification of proinsulin. In this scenario, the ER is intended to perform the function that is normally carried out by secretory granules in specialised secretory cells. Administration of a small drug leads to the dissociation of proinsulin aggregates and their translocation to Golgi. Following processing of proinsulin in Golgi, mature insulin is quickly released in abundance such that insulin is detectable in blood within 15 min of drug administration and peaks by 2 h leading to a 90% decrease in blood glucose levels. Circulating insulin decreases and glucose levels start to rise up again upon drug withdrawal. Therefore, kinetics of insulin secretion in this model closely resembles that observed with natural insulin secretion. Ultimately, glucose-stimulated insulin gene expression combined with a drug-induced system has great potential to simulate pancreatic beta cell function. Controlled transcription and translation of proinsulin, presence of a regulated secretory pathway and inductive secretion are the major notable features of the pancreatic beta cells (Fig. 4) . Although hepatocytes possess glucosesensing machinery composed of GK and GLUT2, they are deprived of the regulated secretory pathway. In addition, neuroendocrine cells can store insulin in secretory granules and manifest a regulated secretory pathway, but they lack a glucose-sensing mechanism. Thus, neither hepatocytes nor neuroendocrine cells can be ideal beta cell surrogates. In contrast, K cells present in duodenum and jejunum are claimed to be outstanding targets for the synthesis and secretion of insulin in a glucose-controlled manner because of GK, GLUT2 and PC expressions just like beta cells (Ref. Ideally, a beta cell substitute (Fig. 4) should also be expected to express glucagon-like peptide 1 (GLP-1) receptors important in regulating postprandial insulin secretion in the presence of glucose (Ref. 55) , and neuronal input is required to control glucose metabolism through pituitary adenylate cyclase-activating polypeptide (PACAP)-and vasoactive intestinal peptide (VIP)-induced pathways under metabolic stress. Insulin is released within minutes after beta cell stimulation, under normal conditions, through the discharge of secretory granules already present in the cytoplasm, making for very rapid kinetics of insulin secretion. Insulin secretion from a surrogate cell, which relies on transcriptional activation, takes place in hours rather than minutes. Turning off the signal through transcriptional inhibition also is a very slow process despite the shorter half-life of preproinsulin mRNA in surrogate beta cells (less than 6 h) than actual beta cells (about 24 h). Nevertheless, insulin secretion is expected to stop in minutes following the signal withdrawal. Since beta cell-specific factors are involved in controlling preproinsulin mRNA stability and processing, gene therapy vectors encoding preproinsulin cDNA should be carefully designed considering all the above-mentioned situations to allow proper regulatory control in surrogate beta cells. Although somatic celltargeted insulin gene therapy with C-peptide (Ref. 56 65, 66, 67) . Furthermore, by using PDX-1 and soluble factors adult human liver cells were successfully transformed into functional insulin-producing cells (Ref. 68) . The fact that hyperglycemia can be ameliorated for a prolonged period of time when these transdifferentiated cells get transplanted under the renal capsule of diabetic mice has raised the possibility of using adult human liver tissue as an alternative for autologous beta-cellreplacement therapy. Apart from liver tissue, reprogramming acinar exocrine cells into beta cells has been successful using agonists of the JAK2/STAT3 signalling pathway (epidermal growth factor and leukaemia inhibitory factor) (Ref. Citation details for this article
